2025. Achievement of On‑Treatment Remission With Risankizumab in Patients With Moderate‑to‑Severe Psoriasis. SKIN The Journal of Cutaneous Medicine. 9, 6 (Nov. 2025), s653. DOI:https://doi.org/10.25251/1ahmv830.